What is the advantage of heterologous prime boost regimes in viral vectored vaccines?1 pointIt reduces the risk of adverse side effectsIt eliminates the need for multiple dosesIt reduces the impact of anti-vector immunity
Question
What is the advantage of heterologous prime boost regimes in viral vectored vaccines?1 pointIt reduces the risk of adverse side effectsIt eliminates the need for multiple dosesIt reduces the impact of anti-vector immunity
Solution
The advantage of heterologous prime boost regimes in viral vectored vaccines is that it reduces the impact of anti-vector immunity.
Here’s a step-by-step explanation:
-
Prime-Boost Strategy: This involves administering a 'prime' dose of a vaccine followed by one or more 'boost' doses. The prime dose initiates an immune response, and the boost doses enhance and prolong this response.
-
Heterologous Regime: In a heterologous prime-boost regime, different vectors (vehicles to deliver the vaccine antigen) are used for the prime and boost doses. For example, the prime dose might use one type of viral vector, and the boost dose might use a different type.
-
Anti-Vector Immunity: When the same vector is used repeatedly, the immune system can develop a response against the vector itself, reducing the effectiveness of subsequent doses. This is known as anti-vector immunity.
-
Reduction of Anti-Vector Immunity: By using different vectors for the prime and boost doses, heterologous regimes minimize the immune system's ability to recognize and neutralize the vector. This ensures that the immune response is focused on the vaccine antigen rather than the vector, enhancing the overall efficacy of the vaccine.
Therefore, the primary advantage of heterologous prime boost regimes is that they reduce the impact of anti-vector immunity, thereby improving the vaccine's effectiveness.
Similar Questions
What is the advantage of developing a vaccine against one of the priority, potential pandemic agents to phase I stage in preparing for a future pandemic with disease X?1 pointPhase I clinical trials can provide early information about the safety and tolerability of the vaccine in humans, allowing for modifications or adjustments to the vaccine if neededPhase I clinical trials can provide information about the spread and epidemiology of disease X in the human population, allowing for targeted vaccination strategiesPhase I clinical trials can provide a more cost-effective approach to vaccine development than later-stage clinical trials, saving resources in pandemic preparedness efforts.Phase I clinical trials can provide a clear understanding of the effectiveness of the vaccine in preventing disease X, allowing for large-scale manufacturing and distribution of the vaccine5.Question 5What is the main advantage of flexi
Which of the following is NOT the primary function of vaccine boosters?To immunize against new mutations in the pathogen.To maintain antibody titers against the pathogen.To develop more memory T cells.To elicit a better secondary immune response during a re-infection.
Which of the following is a way that telescoping vaccine trial programs accelerate pandemic vaccine deployment?1 pointTelescoping vaccine trial programs can streamline the clinical trial process by combining multiple phases of clinical testing into a single trial, reducing the time and resources needed for vaccine developmentTelescoping vaccine trial programs can provide additional funding and resources for vaccine development, allowing for larger and more robust clinical trialsTelescoping vaccine trial programs can accelerate vaccine deployment by skipping regulatory approvals and distributing vaccines to the population at large without adequate safety and efficacy testing.Telescoping vaccine trial programs can help to identify the most promising vaccine candidates early in the development process, reducing the risk of investing in unsuccessful vaccine candidates7.Question 7
A vaccine is effective because ________.Group of answer choicesthe secondary response of the adaptive immunity is faster and more efficient than the primary responsethe vaccine contains the lymphocytes necessary to fight infectionthe vaccine contains the antibodies necessary to fight infectionB-lymphocytes are unable to mount an immune response the first time they are exposed to a new pathogen
Using your knowledge of the third line of defence, explain why a different vaccine needs to be developed for each infectious disease.
Upgrade your grade with Knowee
Get personalized homework help. Review tough concepts in more detail, or go deeper into your topic by exploring other relevant questions.